Jiao Qian

Jiao Qian


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
YSYue Shen
Yue Shen
WJWen-Li Jiang
Wen-Li Jiang
XLXin Li
Xin Li
ACAi-Lin Cao
Ai-Lin Cao
DLDan Li
Dan Li
JQJiao Qian
Jiao Qian
Review Article Mitochondrial dynamics in neurological diseases: a narrative review Yue Shen, Wen-Li Jiang, Xin Li, Ai-Lin Cao, Dan Li, Shang-Ze Li, Jun Yang, Jiao Qian

6 February 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
SLShangze Li
Shangze Li
WJWenli Jiang
Wenli Jiang
FCFei Chen
Fei Chen
JQJiao Qian
Jiao Qian
JYJun Yang
Jun Yang
Intervertebral disc degeneration (IVDD) is a leading cause of chronic back pain, contributing significantly to reduced quality of life and global public health burdens. The TRIM (Tripartite Motif-containing) protein family, with its diverse regulatory roles, has emerged as a key player in critical cellular processes such as inflammation, cell death, and extracellular matrix (ECM) metabolism. Recent findings underscore the involvement of TRIM proteins in IVDD pathogenesis, where they regulate stress responses, maintain cellular homeostasis, and influence the functional integrity of nucleus pulposus (NP) and annulus fibrosus (AF) cells. This review explores the multifaceted roles of TRIM proteins in IVDD, highlighting their contributions to pathological pathways and their potential as therapeutic targets. Advancing our understanding of TRIM protein-mediated mechanisms may pave the way for innovative and precise therapeutic strategies to combat IVDD.

20 December 2025 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
XCXi Cheng
Xi Cheng
YWYuchong Wang
Yuchong Wang
JQJiao Qian
Jiao Qian
RBRong Bai
Rong Bai

1 August 2020 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
GQGang Qiu
Gang Qiu
YYYi-Dan Yan
Yi-Dan Yan
XZXue-Feng Zhang
Xue-Feng Zhang
MSMing Shen
Ming Shen
JQJiao Qian
Jiao Qian
ZGZhi-Chun Gu
Zhi-Chun Gu
Successful thrombolytic therapy in acute ischemic stroke after reversal of warfarin: a case report Gang Qiu, Yi-Dan Yan, Xue-Feng Zhang, Ming Shen, Jiao Qian, Xiao-Dong Ma, Zhi-Chun Gu

1 October 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
XHXi He
Xi He
ADAleksandra K Drelich
Aleksandra K Drelich
QCQing Chang
Qing Chang
DGDejun Gong
Dejun Gong
YZYixuan Zhou
Yixuan Zhou
BGBin Gong
Bin Gong
Rationale: To maintain vascular patency, endothelial cells (ECs) actively regulate hemostasis. Among the myriad of pathways by which they control both fibrin formation and fibrinolysis is EC expression of annexin A2 (ANXA2) in a heterotetrameric complex with S100A10 [(ANXA2-S100A10) 2 ]. This complex is a well-recognized endothelial surface platform for the activation of plasminogen by tissue plasminogen activator. A noteworthy advance in this field came about when it was shown that the cAMP pathway is linked to the regulation of (ANXA2-S100A10) 2 in ECs. Objective: These findings prompted us to determine whether a druggable target, namely the exchange p rotein directly a ctivated by c AMP (EPAC) pathway, plays a role in vascular luminal fibrinolysis. Methods and Results: Taking advantage of our Epac1-null mouse model, we found that depletion of Epac1 results in fibrin deposition, fibrinolytic dysfunction, and decreased endothelial surface ANXA2 in mice, which are similar to phenomena discovered in ANXA2 -null and S100A10 -null mice. We observed upregulation of EPAC1 and downregulation of fibrin in endocardial tissues beneath atrial mural thrombi in humans. Of note, our thrombosis model revealed that dysfunction of fibrinolysis in EPAC1 -null mice can be ameliorated by recombinant ANXA2. Furthermore, we demonstrated that suppression of EPAC1 using a small-molecule inhibitor (ESI09) reduces the expression of ANXA2 in lipid rafts and impedes ANXA2 association with S100A10. Endothelial apical surface expression of both ANXA2 and S100A10 were markedly decreased in ESI09-treated ECs, which was corroborated by results from a nanoforce spectroscopy study. Moreover, inactivation of EPAC1 decreases tyrosine 23 phosphorylation of ANXA2 in the cell membrane compartment. Conclusions: Our data reveal a novel role for EPAC1 in vascular fibrinolysis, by showing that EPAC1 is responsible for the translocation of ANXA2 to the EC surface. This process promotes conversion of plasminogen to plasmin, thereby enhancing local fibrinolytic activity.